Alphatec Hldgs Inc Stock Price, News & Analysis

Alphatec Holdings (Nasdaq: ATEC) will report Q3 2025 financial results on October 30, 2025 after market close and will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET. Replay will be available on the company's Investor Relations website for 12 months.

Management will present at the North American Spine Society meeting on Nov 14, 2025, the Piper Sandler Healthcare Conference on Dec 2, 2025, and the Stifel MedTech Madness West Coast Tour on Dec 8, 2025. The Board approved inducement grants of 47,106 RSUs to 38 new non‑executive employees, vesting annually over four years and fully vesting on a change of control.

Alphatec Holdings (NASDAQ: ATEC), a spine surgery solutions provider, announced its participation in several upcoming investor conferences in August and September 2025. The company will attend the Needham Virtual MedTech Conference, RBCCM Medical Supplies Symposium, Piper Sandler MedTech Tour, and Wells Fargo Healthcare Conference.

Additionally, ATEC announced the grant of 11,967 restricted stock units (RSUs) to 9 new non-executive employees as employment inducement awards. The RSUs will vest over four years in equal annual installments, with full vesting upon a change of control.

Alphatec Holdings (NASDAQ: ATEC), a spine surgery solutions provider, reported strong Q2 2025 financial results and raised its full-year guidance. The company achieved surgical revenue growth of 29% to $168 million and total revenue growth of 27.5% to $186 million.

Key highlights include a 70% gross margin, 13% adjusted EBITDA margin (expanding 880 basis points year-over-year), and $5 million in free cash flow. The company inflected to non-GAAP net income profitability with $3 million in non-GAAP net income.

ATEC raised its full-year 2025 guidance, now expecting total revenue of $742 million (21% growth) and adjusted EBITDA of $83 million, up from previous expectations of $734 million and $78 million respectively.

Alphatec Holdings (NASDAQ: ATEC), a spine surgery solutions provider, will release its Q2 2025 financial results on July 31, 2025, after market close. The company will host a live webcast at 1:30 PM PT / 4:30 PM ET the same day.

Additionally, ATEC announced the grant of 61,096 restricted stock units (RSUs) to 37 new non-executive employees as employment inducement awards. The RSUs will vest over four years in equal annual installments, with full vesting triggered by a change of control.

ATEC (Alphatec Holdings) reported strong Q1 2025 financial results with significant growth metrics. Total revenue reached $169 million, representing 22% growth, while surgical revenue grew 24%. The company demonstrated solid operational performance with a 69% GAAP gross margin and achieved an Adjusted EBITDA of $11 million with a 6% margin, showing an 840 basis points improvement year-over-year. Key highlights include 17% growth in procedural volume and 18% increase in new surgeon adoption. Based on strong performance, ATEC raised its full-year 2025 guidance, now expecting total revenue of $734 million (20% growth) and adjusted EBITDA of approximately $78 million. The company also successfully refinanced its convertible debt to 2030 maturity and improved free cash use by $55 million compared to Q1 2024.

Alphatec Holdings (ATEC) has announced the commercial launch of its Prone TransPsoas (PTP™) Corpectomy system, expanding its capabilities for complex thoracolumbar spine procedures. The system includes three key components:

1. The Sigma™ LIF Corpectomy Access System for optimized lateral corpectomy exposure

2. The Ascend™ NanoTec™ Vertebral Body Replacement (VBR) System featuring anatomy-driven, expandable design with NanoTec surface treatment

3. The SafeOp™ Neural InformatiX™ System providing real-time monitoring and nerve health assessment

The integrated solution aims to enhance surgical workflow, visualization, and patient outcomes in complex spine surgeries involving tumor, trauma, infection, and deformity cases.

Alphatec Holdings (ATEC) has scheduled its first quarter 2025 financial results announcement for May 1, 2025, after market close. The company will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day.

Additionally, ATEC's independent Compensation Committee has approved inducement awards for 17 new non-executive employees, granting a total of 45,636 restricted stock units (RSUs). These RSUs will vest in equal annual installments over four years, contingent on continued employment. Full vesting will occur immediately upon a change of control of the company.

Alphatec Holdings (ATEC) has priced an upsized offering of $350 million convertible senior notes due 2030, increased from the previously announced $300 million. The notes will carry a 0.75% annual interest rate, payable semi-annually, and mature on March 15, 2030.

The initial conversion rate is 64.3407 shares per $1,000 principal amount, representing a conversion price of $15.54 per share - a 32.5% premium over ATEC's closing price of $11.73. The company expects net proceeds of approximately $339 million, which will be used to fund capped call transactions ($36.7 million), repurchase existing 2026 notes ($268.4 million), and general corporate purposes.

ATEC has entered into capped call transactions to reduce potential dilution and offset cash payments upon conversion. The cap price is set at $23.46 per share, representing a 100% premium over the current stock price.

Alphatec Holdings (ATEC) has announced plans to offer $300 million in convertible senior notes due 2030 to qualified institutional buyers, with an option for purchasers to buy an additional $50 million. The notes will be senior, unsecured obligations with semi-annual interest payments.

The notes will be convertible into cash, ATEC common stock, or a combination thereof. Conversion rights activate upon certain events before September 17, 2029, and at any time thereafter until maturity. ATEC can redeem the notes after March 20, 2028, if stock price conditions are met.

The company plans to enter into capped call transactions to reduce potential dilution. Proceeds will be used to: (1) fund capped call transactions, (2) repurchase a portion of existing 0.75% convertible notes due 2026, and (3) general corporate purposes.